Investigation Launched by Pomerantz Law Firm for Fulgent Genetics Investors Amid Securities Fraud Concerns

Investor Alert: Pomerantz Law Firm Investigates Fulgent Genetics, Inc.

Pomerantz LLP has announced an investigation into claims concerning Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of its investors. This inquiry aims to determine if the company and its leadership engaged in securities fraud or any unlawful business practices.

In a surprising turn of events, Fulgent Genetics revealed in its annual report submitted to the U.S. Securities and Exchange Commission (SEC) that it had received a civil investigative demand from the U.S. Department of Justice. This investigation pertains to allegations of false claims submitted through the Uninsured Program. The news had a significant impact, causing Fulgent's stock price to decrease by $0.41, or 2.61%, following the announcement on February 28, 2025, closing at $15.28 on March 3, 2025.

As a leading firm in corporate and securities law, Pomerantz LLP has a long-standing reputation for advocating for victims of securities fraud and corporate misconduct. Established by the late Abraham L. Pomerantz, known as a pioneer in the field of securities class actions, the firm continues to uphold his legacy over 85 years later. They have secured numerous multimillion-dollar damage awards for class action members, showcasing a commitment to justice and accountability in the financial sector.

The firm is encouraging investors affected by Fulgent Genetics to reach out for additional information and to discuss potential participation in a class action lawsuit. Interested parties can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980.

Financial and corporate fraud can have devastating effects on investors, and it is crucial for affected individuals to seek guidance and support during such challenging times. Pomerantz LLP's team of skilled attorneys is committed to advocating for the rights of investors while navigating the complexities of securities litigation.

Those who have invested in Fulgent Genetics and suffered financial losses may find this investigation to be a pivotal step towards reclaiming their rights. Monitoring updates and engaging with legal experts can make a significant difference in the outcome of such cases.

Stay informed about developments regarding Fulgent Genetics and the ongoing investigation by following reputable financial news sources. With the right legal backing, investors can unite to hold companies accountable for any wrongdoings, signaling a strong message against securities fraud in the marketplace.

In conclusion, Pomerantz LLP remains steadfast in its mission to protect investors' rights, and its fresh investigation into Fulgent Genetics serves as a reminder of the importance of transparency and accountability in the corporate world.